Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FluCAM · 1 trial · 1 indication
Progression-free survival was defined as the number of days from the date of randomization to the date of first objective documentation of progressive disease (PD) as determined by the treatment-blinded IRRP, or death due to any cause. Results are expressed in months.
| Arm | Type | Description |
|---|---|---|
| Combination Arm (FluCAM) | EXPERIMENTAL | - |
| Fludarabine Alone | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| FluCAM [Fludara + Campath] | BIOLOGICAL | Phase A: Escalating Doses of alemtuzumab (Campath) Alone Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours. Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated. Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated. Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days. Phase B: FluCAM Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity. |
| fludarabine phosphate | BIOLOGICAL | Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity. |
Inclusion Criteria: * A diagnosis of B-cell chronic lymphocytic leukemia (B-CLL); according to the National Cancer Institute Working Group (NCI WG) criteria. * Relapsed or refractory disease after 1 prior regimen except patients who were refractory to (i.e., progressed on) fludarabine or alemtuzuma...
FluCAM is a monoclonal antibody being studied for the treatment of B-Cell Chronic Lymphocytic Leukemia. It is currently in Phase 3 clinical development and is being investigated as a combination therapy with fludarabine for this condition.
FluCAM is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 3 clinical trials for B-Cell Chronic Lymphocytic Leukemia.
FluCAM is in Phase 3 clinical development. It is an investigational drug being studied for B-Cell Chronic Lymphocytic Leukemia, and it has not yet been approved by regulatory authorities.
FluCAM is being studied in a Phase 3 clinical trial with the identifier NCT00086580. This trial compares fludarabine plus FluCAM against fludarabine alone in patients with B-Cell Chronic Lymphocytic Leukemia. The study has been completed and enrolled 335 participants.
FluCAM is a monoclonal antibody that targets a specific protein on the surface of cancer cells. By binding to this target, it helps the immune system recognize and attack the malignant cells in B-Cell Chronic Lymphocytic Leukemia.